Bausch Health Companies (NYSE:BHC) Upgraded at StockNews.com

StockNews.com upgraded shares of Bausch Health Companies (NYSE:BHC) from a hold rating to a buy rating in a research report released on Wednesday morning.

BHC has been the subject of a number of other reports. Truist Financial decreased their price objective on shares of Bausch Health Companies from $8.00 to $7.00 and set a hold rating for the company in a research report on Thursday, July 25th. Royal Bank of Canada reduced their price target on Bausch Health Companies from $10.00 to $8.50 and set a sector perform rating for the company in a report on Friday, August 2nd. Jefferies Financial Group dropped their price objective on Bausch Health Companies from $13.00 to $9.00 and set a buy rating on the stock in a report on Wednesday, August 7th. Scotiabank reduced their target price on Bausch Health Companies from $10.00 to $8.50 and set a sector perform rating for the company in a research note on Friday, August 2nd. Finally, Raymond James began coverage on shares of Bausch Health Companies in a research note on Wednesday, July 10th. They issued a market perform rating and a $8.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bausch Health Companies currently has a consensus rating of Hold and a consensus price target of $7.33.

Bausch Health Companies Trading Up 1.8 %

NYSE:BHC opened at $8.26 on Wednesday. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The firm has a market capitalization of $2.98 billion, a price-to-earnings ratio of -6.66 and a beta of 0.75. The firm’s fifty day simple moving average is $6.34 and its 200 day simple moving average is $7.30.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.33 billion. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. During the same quarter in the prior year, the business earned $0.81 earnings per share. On average, analysts predict that Bausch Health Companies will post 3.61 earnings per share for the current year.

Insider Activity

In related news, EVP Seana Carson sold 13,370 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the transaction, the executive vice president now directly owns 435,198 shares in the company, valued at $2,702,579.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.12% of the company’s stock.

Institutional Trading of Bausch Health Companies

Institutional investors and hedge funds have recently modified their holdings of the business. Salem Investment Counselors Inc. acquired a new position in shares of Bausch Health Companies in the 1st quarter valued at about $32,000. Headlands Technologies LLC bought a new position in Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC acquired a new position in Bausch Health Companies in the second quarter valued at approximately $71,000. Certuity LLC bought a new position in shares of Bausch Health Companies during the second quarter valued at approximately $75,000. Finally, Bfsg LLC raised its position in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after purchasing an additional 3,643 shares during the period. 78.65% of the stock is owned by institutional investors and hedge funds.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.